Press release
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif., April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced
About this update from Amgen Inc.
[{"type":"text","content":"Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs \nTHOUSAND OAKS, Calif., April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 billion.\n\n \n \n \n \n \n \n\n \n\"Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today's investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines,\" said Robert A. Bradway, chairman and chief executive officer at Amgen. \"Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.\" \nAmgen first entered Ohio in June 2021, when it announced plans to invest in a state-of-the-art biomanufacturing facility in Central Ohio. This investment marked the company's expansion into the Columbus Region, which enhanced its U.S.-based manufacturing capabilities and created 400 jobs upon the facility's opening. \n\"Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth,\" said Ohio Governor Mike DeWine. \"We are happy to see Amgen deepen its commitment to our state and look forward to the innovation and economic impact it will drive.\"\nSince passage of the Tax Cuts and Jobs Act of 2017, Amgen has invested almost $5 billion in direct capital expenditures in the United States, generating an additional downstream output to the U.S. economy of approximately $12 billion.\nThe Ohio expansion enhances the company's global biomanufacturing network, leveraging decades of operational expertise and technological advancements and follows the company's recent announcement that it would invest $1 billion to build a second manufacturing plant in Holly Springs, NC. With these investments across the U.S., Amgen is focused on building the most cutting-edge biologics manufacturing capabilities in the world.\nAbout Amgen \nAmgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establi...